Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone Participatns with Relasped Refractory or Ineligible for Autologous Stem Cell Transplant
Clinical Trial Grant
Awarded By
The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership
Start Date
June 20, 2018
End Date
September 9, 2020
Awarded By
The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership
Start Date
June 20, 2018
End Date
September 9, 2020